Updates are available Correction dated 2024-03-31

Article History

Received: 24 August 2023

Accepted: 24 November 2023

First Online: 11 January 2024

Change Date: 31 March 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00280-024-04645-9

Declarations

:

: Noboru Yamamoto declares employment/leadership position/advisory role with Eisai, Takeda, Otsuka, Boehringer Ingelheim, Cimic and Chugai Pharmaceutical Co., Ltd. Noboru Yamamoto also declares honoraria from AstraZeneca, Eli Lilly, ONO, Chugai, Sysmex, Daiichi-Sankyo, Eisai and research funding from Astellas, Chugai Pharmaceutical Co., Ltd., Eisai, Taiho, Bristol–Myers Squibb, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa-Hakko Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Dainippon, Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi and TORAY. Takafumi Koyama declares honoraria from Sysmex and Chugai Pharmaceutical Co., Ltd., and research funding from PACT Pharma, Chugai Pharmaceutical Co., Ltd., Lilly, Novartis, Takeda, and Daiichi-Sankyo. Jun Sato declares receipt of lecture fees from Chugai Pharmaceutical Co., Ltd. Tatsuya Yoshida declares honoraria from Pfizer, Takeda, AstraZeneca, TAIHO, Chugai Pharmaceutical Co., Ltd., Novartis, Lilly, MSD, Ono Pharmaceutical, Roche, and Bristol–Myers Squibb; and research funding from AMGEN, AstraZeneca, Takeda, Chugai Pharmaceutical Co., Ltd., Novartis, Daiichi-Sankyo, Ono Pharmaceutical, AbbVie, Blueprint, and Bristol–Myers Squibb. Kazuki Sudo declares no conflict of interest. Satoru Iwasa declares receipt of lecture fees from Chugai Pharmaceutical Co., Ltd. Shunsuke Kondo declares honoraria from Eisai, Incyte and Chugai Pharmaceutical Co., Ltd.; and research funding from Astellas, Incyte, AstraZeneca, MSD, Daiichi-Sankyo, Eisai, AbbVie, Lilly and Bristol–Myers Squibb. Kan Yonemori declares advisory roles at Novartis, Eisai, AstraZeneca, Chugai Pharmaceutical Co., Ltd., Takeda, Genmab, and OncXerna; honoraria from Pfizer, Eisai, AstraZeneca, Eli Lilly, Takeda, Chugai Pharmaceutical Co., Ltd., Fuji Film Pharma, MSD, Boehringer Ingelheim, Ono, and Daiichi-Sankyo; and research funding from AstraZeneca, Taiho, Pfizer, Novartis, Takeda, Chugai Pharmaceutical Co., Ltd., Ono, Sanofi, Seattle Genetics, Eisai, Eli Lilly, Genmab, Boehringer Ingelheim, and Kyowa Hakko. Atsuko Kawasaki, Shoyo Shibata and Kyoko Satake are employees of Chugai Pharmaceutical Co., Ltd. Toshio Shimizu declares employment/leadership/advisory role from AbbVie, Daiichi-Sankyo and Chordia Therapeutics and honoraria from Eli Lilly, MSD and Chugai. Toshio Shimizu also declares research funding from Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bristol-Myers Squibb, Eisai, AstraZeneca, Takeda Oncology, Incyte, Chordia Therapeutics, 3D-Medicine, Symbio Pharmaceuticals, PharmaMar, Pfizer, Five Prime and Astellas Pharma.

: The study protocol was reviewed and approved by the institutional review board or independent ethics committee at the study center, and the study was conducted according to the ethical principles of the Declaration of Helsinki.

: All patients provided written informed consent.